Roger S. Day, ScD

Room 532
5607 Baum Boulevard
Phone: 
412-624-3253
Fax: 
412-624-5310
Admin Support: 
Research Interests: 
  • High throughput identifier mapping
  • Ethical design and execution of clinical trials
  • Applications of biostatistics in cancer research 
  • Software architecture for comprehensive modeling and validation
  • Multi-scale modeling in cancer
  • Strategies for overcoming drug resistance in cancer
  • How pharmaceutical and biological interactions should be statistically modeled
Associate Professor
Department of Biomedical Informatics
University of Pittsburgh School of Medicine
Publications: 

Day, R. S. (2016). Planning clinically relevant biomarker validation studies using the “number needed to treat” concept. Journal of Translational Medicine, 14, 117. PMID: 27146704 PMCID: PMC4857295 DOI: 10.1186/s12967-016-0862-4

Day, RS., Want a letter? You write it for me. Science. 2016 Jan 8;351(6269):198. PMID: 26744407 DOI: 10.1126/science.351.6269.198

Archer, K. J., Dobbin, K., Biswas, S., Day, R. S., Wheeler, D. C., & Wu, H. (2015). Computer Simulation, Bioinformatics, and Statistical Analysis of Cancer Data and Processes. Cancer Informatics, 14(Suppl 2), 247–251. PMID: 26380548 PMCID: PMC4559198 DOI: 10.4137/CIN.S32525

Day, R. S. (2015). What Tumor Dynamics Modeling Can Teach us About Exploiting the Stem-Cell View for Better Cancer Treatment. Cancer Informatics, 14(Suppl 2), 25–36.  PMID: 25780337 PMCID: PMC4345852 DOI: 10.4137/CIN.S17294

McDade, K. K., Chandran, U., & Day, R. S. (2015). Improving Cancer Gene Expression Data Quality through a TCGA Data-Driven Evaluation of Identifier Filtering. Cancer Informatics, 14, 149–161.  PMID: 26715829 PMCID: PMC4686346 DOI: 10.4137/CIN.S33076

McDade KK, Chandran U, Day RS. Improving Cancer Gene Expression Data Quality through a TCGA Data-Driven Evaluation of Identifier Filtering. Cancer Informatics, 2015. PMID: 26715829 PMCID: PMC4686346

Osmanbeyoglu, H. U., Lu, K. N., Oesterreich, S., Day, R. S., Benos, P. V., Coronnello, C., & Lu, X. (2013). Estrogen represses gene expression through reconfiguring chromatin structures. Nucleic Acids Research, 41(17), 8061–8071. PMID: 23821662 PMCID: PMC3783169 DOI: 10.1093/nar/gkt586

Day, R. S., & McDade, K. K. (2013). A decision theory paradigm for evaluating identifier mapping and filtering methods using data integration. BMC Bioinformatics, 14, 223.  PMID: 23855655 PMCID: PMC3734162 DOI: 10.1186/1471-2105-14-223

Buch, S. C., Diergaarde, B., Nukui, T., Day, R. S., Siegfried, J. M., Romkes, M., & Weissfeld, J. L. (2012). Genetic variability in DNA repair and cell cycle control pathway genes and risk of smoking-related lung cancer. Molecular Carcinogenesis, 51(Suppl 1), E11–E20.  PMID: 21976407 PMCID: PMC3289753 DOI: 10.1002/mc.20858

Lisovich,A. and Day,R.S. The IdMappingAnalysis package: critically comparing identifier maps retrieved from bioinformatics annotation resources.  R package Version 1.1.1., in Bioconductor Release 2.11, 2012.

Maxwell GL,  HoodBL, DayR, et al.  Proteomic analysis of stage I endometrial cancer tissue: Identification of proteins associated with oxidative processes  and inflammation.  Gynecol Oncol.2011. Jun 1;121(3):586-94.Epub 2011 Apr1.PMCID:PMC21458040

DayRS,McDade KK,Chandran UR, Lisovich A, ConradsTP, Hood BL,Kumar Kolli VS,KirchnerD, Litzi T, Maxwell GL. Identifier performance for integrating ranscriptomics and proteomics experimental results.  BMC Bioinformatics.2011May27;12(1):213.PMCID:PMC3124437

Day RS, McDade KK, Chandran UR, Lisovich A, Conrads TP, Hood BL, Kolli VS, Kirchner D, Litzi T, Maxwell GL. (2011). Identifier mapping performance for integrating transcriptomics and proteomics experimental results. BMC Bioinformatics, 12, 213. http://doi.org/10.1186/1471-2105-12-213 PMID: 21619611 PMCID: PMC3124437

Lisovich,A. and Day,R.S. The IdMappingRetrieval package inBioconductor: Collecting and caching identifier mappings from online sources. R package Version 1.3.1, in Bioconductor Release 2.9, 2011.

Wang M, Day RS.  Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.   2010 Jan.  J Bioppharm Stat. 20(1), 125-44.

Day R.  Failsafe automation of Phase II clinical trial interim monitoring for stopping rules. Clin Trials 2010, 7(1), 78-84.

^